Severe asthma in children

Paediatrics and Child Health

Volumn 17, Issue 5, 2007, Pages 180-187

  Paton, James Y ^a  

^a NONE

Author keywords

asthma; children; difficult; severe; therapy resistant

Indexed keywords

ETANERCEPT; INFLIXIMAB; OMALIZUMAB; TRIAMCINOLONE;

ARTICLE; BEHAVIOR MODIFICATION; CHILD; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; EDUCATION PROGRAM; HUMAN; KINESIOTHERAPY; LIFESTYLE; LUNG FUNCTION TEST; PATIENT EDUCATION; REHABILITATION CARE; SEVERE PERSISTENT ASTHMA;

EID: 34248569503     PISSN: 17517222     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.paed.2007.02.004     Document Type: Article

References (40)

1. British guideline on the management of asthma. Thorax 2003;58 (Suppl 1):i1-4.
2. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000; 16: 802-7.
3. Global strategy for asthma management and prevention. Report No.: 0203659, Maryland. Bethesda: National Intitues of Health; 2002.
4. Colice GL. Categorizing asthma severity: an overview of national guidelines. Clin Med Res 2004; 2: 155-63.
5. Galant SP, Morphew T, Amaro S, Liao O. Current asthma guidelines may not identify young children who have experienced significant morbidity. Pediatrics 2006; 117: 1038-45.
6. Bacharier LB, Strunk RC, Mauger D, et al. Classifying asthma severity in children: mismatch between symptoms, medication use, and lung function. Am J Respir Crit Care Med 2004; 170: 426-32.
7. Jenkins HA, Cherniack R, Szefler SJ, et al. A comparison of the clinical characteristics of children and adults with severe asthma. Chest 2003; 124: 1318-24.
8. Cockcroft DW, Swystun VA. Asthma control versus asthma severity. J Allergy Clin Immunol 1996; 98: 1016-8.
9. Robertson CF, Rubinfeld AR, Bowes G. Pediatric asthma deaths in Victoria: the mild are at risk. Pediatr Pulmonol 1992; 13: 95-100.
10. Baker KM, Brand DA, Hen Jr J. Classifying asthma: disagreement among specialists. Chest 2003; 124: 2156-63.
11. Gibson NA, Ferguson AE, Aitchison TC, Paton JY. Compliance with inhaled asthma medication in preschool children. Thorax 1995; 50: 1274-9.
12. Chung KF, Godard P, Adelroth E, et al. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society. Eur Respir J 1999; 13: 1198-208.
13. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160: 1001-8.
14. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006; 368: 804-13.
15. Payne D, Bush A. Phenotype-specific treatment of difficult asthma in children. Paediatr Respir Rev 2004; 5: 116-23.
16. Gibson PG, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001; 119: 1329-36.
17. Gibson PG, Simpson JL, Hankin R, et al. Relationship between induced sputum eosinophils and the clinical pattern of childhood asthma. Thorax 2003; 58: 116-21.
18. Zacharasiewicz A, Wilson N, Lex C, et al. Clinical use of noninvasive measurements of airway inflammation in steroid reduction in children. Am J Respir Crit Care Med 2005; 171: 1077-82.
19. Taylor DR, Pijnenburg MW, Smith AD, de Jongste JC. Exhaled nitric oxide measurements: clinical application and interpretation. Thorax 2006; 61: 817-27.
20. Lex C, Ferreira F, Zacharasiewicz A, et al. Airway eosinophilia in children with severe asthma: predictive values of noninvasive tests. Am J Respir Crit Care Med 2006; 174: 1286-91.
21. Pijnenburg MW, Hofhuis W, Hop WC, de Jongste JC. Exhaled nitric oxide predicts asthma relapse in children with clinical asthma remission. Thorax 2005; 60: 215-8.
22. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360: 1715-21.
23. Payne DN, Adcock IM, Wilson NM, et al. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone. Am J Respir Crit Care Med 2001; 164: 1376-81.
24. Coren ME, Rosenthal M, Bush A. The use of cyclosporin in corticosteroid dependent asthma. Arch Dis Child 1997; 77: 522-3.
25. Douwes J, Gibson P, Pekkanen J, Pearce N. Non-eosinophilic asthma: importance and possible mechanisms. Thorax 2002; 57: 643-8.
26. Robinson DS, Campbell DA, Durham SR, et al. Systematic assessment of difficult-to-treat asthma. Eur Respir J 2003; 22: 478-83.
27. Heaney LG, Conway E, Kelly C, et al. Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol. Thorax 2003; 58: 561-6.
28. Roberts NJ, Robinson DS, Partridge MR. How is difficult asthma managed? Eur Respir J 2006; 28: 968-73.
29. Saglani S, Nicholson AG, Scallan M, et al. Investigation of young children with severe recurrent wheeze: any clinical benefit? Eur Respir J 2006; 27: 29-35.
30. Everard ML. Role of inhaler competence and contrivance in "difficult asthma". Paediatr Respir Rev 2003; 4: 135-42.
31. Thomson NC, Spears M. The influence of smoking on the treatment response in patients with asthma. Curr Opin Allergy Clin Immunol 2005; 5: 57-63.
32. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 2006; 368: 780-93.
33. Wright RJ, Rodriguez M, Cohen S. Review of psychosocial stress and asthma: an integrated biopsychosocial approach. Thorax 1998; 53: 1066-74.
34. Schatz M, Sorkness CA, Li JT, et al. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol 2006; 117: 549-56.
35. Panickar JR, Kenia P, Silverman M, Grigg J. Intramuscular triamcinolone for difficult asthma. Pediatr Pulmonol 2005; 39: 421-5.
36. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001; 108: E36.
37. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309-16.
38. Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005; 60: 1012-8.
39. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006; 354: 697-708.
40. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med 162 (2000) 2341-2351